Trial reportBMC cancer2025
Albumin-bound paclitaxel and cisplatin with radiotherapy in locally advanced oesophageal squamous cell carcinoma: a single-arm, phase II trial.
Trial report in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundWe conducted a Phase II study to assess the efficacy and toxicity of nab-paclitaxel (nab-PTX) and cisplatin in combination with concurrent radiotherapy in patients with locally advanced oesophageal squamous cell carcinoma (ESCC).
methodsForty-two patients with locally advanced ESCC received nab-paclitaxel (75 mg/m²) and cisplatin (25 mg/m²) on days 1, 8, 15, 22, and 29 of radiotherapy, with total radiation doses ranging from 50 to 64 Gy. The overall response rate (ORR) and disease control rate (DCR) were defined as primary endpoints, while progression-free survival (PFS), overall survival (OS), and treatment-related toxicity were considered secondary endpoints.
resultsBetween February 2019 and April 2023, 42 patients who met the inclusion criteria participated in the study, 36 (85.7%) of whom were male, with a median age of 62.5 years (IQR: 57.0-66.3). All participants were classified as having clinical stage III or IV disease. Of the 42 patients, 28 (66.7%) completed all planned chemoradiotherapy sessions, whereas 35 (83.4%) completed at least four cycles of chemotherapy, with a median of five cycles (range: 1-5). In the efficacy assessment, the ORR was 73.8%, and the DCR was 90.5%. After a median follow-up of 28.1 months (IQR: 19.9-55.8), the 1-year PFS and 1-year OS rates were 57.1% and 88.0%, respectively. The most common grade 3 or 4 adverse event (AE) was leukopenia (38.1%), with no treatment-related deaths observed.
conclusionsThe combination of nab-paclitaxel and cisplatin, administered on a weekly schedule with concurrent radiotherapy, demonstrated promising antitumour activity and an acceptable safety profile in patients with ESCC.
trial registrationThe trial was registered at https://clinicaltrials.gov under the identifier ChiCTR1900021079 in January 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.